Click Here for a detailed listing of studies, formatted as a .pdf

Breast Cancer

AMG 162: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence (D-CARE)

CRAD001J 2301: A Randomized Phase III, Double-Blind, Placebo-Controlled Multicenter Trial of Everolimus in Combination with Trastuzumab and Paclitaxel, as First Line Therapy in Women with HER2 Positive Locally Advanced or Metastatic Breast Cancer

PT-304: Prediction of Response to Neoadjuvant Chemotherapy in Women with Operable Breast Cancer

ACOSOG Z1071: A Phase II Study Evaluating the Role of Sentinel Lymph Node Surgery and Axillary Lymph Node Dissection Following Preoperative Chemotherapy in Women with Node Positive Breast Cancer (T1-4, N1-2, M0) at Initial Diagnosis.

Lumpectomy and Brachytherapy as Salvage Treatment for Local Recurrences Following Breast Conservative Therapy

Investigating Radiation Therapy: The Accelerated RT Trial

Understanding Cognition: The Columbia Cognitive

Mammary Ductoscopy and Intraductal Biopsy for Women at High Risk for Developing Breast Cancer, for Women Presenting with Spontaneous Nipple Discharge, and for Women Diagnosed with Breast Cancer Undergoing Surgery to the Contralateral Breast

GI/Colon

A Phase II Study For Patients With Advanced Rectal Cancer Using Pre-Operative High Dose Rate Brachytherapy + Folfox Chemotherapy

Phase III Randomized Study Of Sorafenib Plus Doxorubicin Versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma (HCC).

A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer.

A Phase III Randomized, Double-Blind Trial of Chemoembolization with or without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients with and without Vascular Invasion.

AB-GIST: A Prospective, Multicenter, Randomized, Open-Label, Active-Controlled, 2-parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib at 7.5 mg/kg/day to Imatinib at 400 or 600 mg in Treatment of Patients With Gastro-intestinal Stromal Tumor in First Line Medical Treatment.

RTOG 0436: A Phase III Trials Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients with Esophageal Cancer Who Are Treated Without Surgery

EZN-2208-04:A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients with Metastatic Colorectal Carcinoma (mCRC)

A Phase 3, Randomized, Double-Blinded Study of IMC-1121B and Best Supportive Care (BSC) Versus Placebo and BSC  in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First-Line Platinum- or Fluoropyrimidine-Containing Combination Therapy

A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX plus or minus GDC-0449 in patients with advanced gastric and gastroesophageal junction (GEJ) carcinoma

Gynecology

A Randomized Phase III Trial Of Cisplatin Plus Paclitaxel With And Without NCI-Supplied Bevacizumab (NSC #704865, IND #7921) Versus The Nonplatinum Doublet, Topotecan Plus Paclitaxel, With And Without NCI-Supplied Bevacizumab, In Stage IVb, Recurrent Or Persistent Carcinoma Of The Cervix

Phase II Trial of Combination Pemetrexed (Alimta) and Carboplatin (Paraplatin) in Platinum Sensitive Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Carcinoma

MORAb-003: A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of MORAb-003 (farletuzumab) in Combination with Paclitaxel Therapy in Subjects with First Platinum-Resistant or Refractory Relapsed Ovarian Cancer

GOG-0263: RANDOMIZED PHASE III CLINICAL TRIAL OF ADJUVANT RADIATION VERSUS CHEMORADIATION IN INTERMEDIATE RISK, STAGE I/IIA CERVICAL CANCER TREATED WITH INITIAL RADICAL HYSTERECTOMY AND PELVIC LYMPHADENECTOMY.

Head and Neck
A Phase 2b, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Three Different Doses of SCV‑07 in Attenuating Oral Mucositis in Subjects With Head and Neck Cancer Receiving Concurrent Chemotherapy and Radiotherapy.

Prospective Evaluation of Unilateral/Ipsilateral Neck Irradiation Combined with Amifostine in Selected Patients with Squamous Cell Carcinoma of the Head and Neck Who are Managed by Radiation Therapy.

RTOG 0920: A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer

A Multi-Institutional Phase II study of Radiation and GW572016 (Lapatinib) for Patients with Stage III-IV Head and Neck Cancer Who Cannot Tolerate Concurrent Chemoradiotherapy

A phase I trial of adjuvant chemotherapy using cetuximab (c) and docetaxel (t) for N2b-3 HNSCC patients with positive pathologic residual neck diseases after concurrent chemoradiation (CRT)

A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer

Hematology
SWOG 0777: A Randomized Phase III Trial of CC-5013 (Lenalidomide, NSC-703813) and Low Dose Dexamethasone (LLD) Versus Bortezomib (PS-341, NSC-681239), Lenalidomide and Low Dose Dexamethasone (BLLD) for Induction, in Patients with Previously Untreated Multiple Myeloma Without an Intent for Immediate Autologous Stem Cell Transplant

TTP: Phase II study of danazol with plasma exchange and steroids for the treatment of thrombotic thrombocytopenic purpura

Lung
Lilly JVBA (IMCL CP12-1027): A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy

A Randomized Phase III Comparison of Standard-Dose (60 Gy) Versus High-Dose (74 Gy) Conformal Radiotherapy With Concurrent and Consolidation Carboplatin/Paclitaxel in Patients With Stage IIIA/IIIB Non-Small Cell Lung Cancer

MAGRIT 109493: A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3-positive Non-Small Cell Lung Cancer

RTOG 0813: Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients

Lymphoma
Calistoga: A Phase 2 Study to Assess the Efficacy and Safety of CAL-101 in Patients with Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents.

SWOG 0816: A Phase II Trial of Response Adapted Therapy of Stage III-lV Hodgkin Lymphoma Using Early Interim FDG-PET Imaging

An Open-Label, Randomized, Phase 2 Study to Assess the Effectiveness of
RCHOP With or Without VELCADE in Previously Untreated Patients with Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma

Prostate
Androgen Receptor Modulation: Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy

Analysis of circulating tumor cells in prostate cancer. Predicting response to taxanes: A Pilot Study

Image-Guided Intensity-Modulated Radiotherapy (IG-IMRT) for Prostate Cancer

Renal
A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of pazopanib as adjuvant therapy for subjects with localized or locally advanced RCC following nephrectomy

Skin
Multicenter, non-randomized, prospective study for the treatment of non-melanoma skin cancer (squamous cell cancer and basal cell cancer) using Xoft Axxent Electronic Brachytherapy Treatment System as the primary treatment for NMSC